BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 08, 2015
 |  BioCentury  |  Finance

Xanthopoulos' passion play

Why Kleanthis Xanthopoulos left Regulus to join Vendel Group

With his role of running Regulus Therapeutics Inc. (NASDAQ:RGLS) in the rearview mirror, Kleanthis Xanthopoulos expects his new job at Vendel Group will be a smaller-scale, California version of what Third Rock Ventures does - creating and running portfolio companies in their initial stages.

Vendel Group is a family office with an undisclosed sum under management.

"What I like to do is run with great ideas that you tell people about and they say 'are you crazy?'" he told BioCentury. "I tried that as a VC and didn't like the model. It takes a lot of time to invest and then you're on a board where...

Read the full 526 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >